🇺🇸 FDA
Patent

US 11077077

Therapeutic compounds, formulations, and uses thereof

granted A61KA61K31/18A61K47/10

Quick answer

US patent 11077077 (Therapeutic compounds, formulations, and uses thereof) held by Tvardi Therapeutics, Inc. expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Tvardi Therapeutics, Inc.
Grant date
Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/18, A61K47/10, A61K47/26, A61K47/44